Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Depressive disorder | D003866 | EFO_1002014 | F32.A | 2 | 1 | — | — | — | 3 |
Depression | D003863 | — | F33.9 | — | 1 | — | — | — | 1 |
Major depressive disorder | D003865 | EFO_0003761 | F22 | — | 1 | — | — | — | 1 |
Irritable bowel syndrome | D043183 | EFO_0000555 | K58 | — | 1 | — | — | — | 1 |
Syndrome | D013577 | — | — | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Anxiety disorders | D001008 | EFO_0006788 | F41.1 | 3 | — | — | — | — | 3 |
Social phobia | D000072861 | EFO_1001917 | F40.1 | 1 | — | — | — | — | 1 |
Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
Drug common name | VERUCERFONT |
INN | verucerfont |
Description | Verucerfont (GSK-561,679) is a drug developed by GlaxoSmithKline which acts as a CRF-1 antagonist. Corticotropin releasing factor (CRF), also known as Corticotropin releasing hormone, is an endogenous peptide hormone which is released in response to various triggers such as chronic stress, and activates the two corticotropin-releasing hormone receptors CRH-1 and CRH-2. This then triggers the release of corticotropin (ACTH), another hormone which is involved in the physiological response to stress.
|
Classification | Small molecule |
Drug class | CRF-1 (corticotropin releasing factor) receptor antagonists |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | CC[C@H](Nc1cc(C)nc2c(-c3ccc(OC)cc3C)c(C)nn12)c1nc(C)no1 |
PDB | — |
CAS-ID | 885220-61-1 |
RxCUI | — |
ChEMBL ID | CHEMBL1287935 |
ChEBI ID | — |
PubChem CID | 11596613 |
DrugBank | — |
UNII ID | X60608B091 (ChemIDplus, GSRS) |